Viewing nowGyeongbo Ibandronate Tablets (Ibandronic Acid Sodium Monohydrate)
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Gyeongbo Pharmaceutical Co., Ltd.

MFDS item code 201306285 · Approved 2013.03.19 · Insurance code 665001720
Treatment of osteoporosis in postmenopausal women
This medication is used to treat osteoporosis occurring in postmenopausal women. The reduction of female hormones due to menopause can lead to weakened bones, and this drug helps increase bone density and reduce the risk of fractures. Therefore, it helps alleviate symptoms related to osteoporosis and maintain healthy bones.
Take 1 tablet once a month, regularly on the same day each month in the morning, with plenty of water at least 1 hour before consuming food, beverages (except water), or other oral medications or dietary supplements (including calcium): - Swallow this medicine with plenty of water (180-240ml) while standing or sitting upright, and do not lie down for 60 minutes after taking it. - Mineral water may reduce the absorption of this medicine, so take it with plain water. - To avoid esophageal ulcers, do not chew or suck the tablet. If the patient forgets to take a dose on the scheduled day: - If 8 days or more remain until the next scheduled dose, take 1 tablet the morning after realizing that the dose was missed. Thereafter, take 1 tablet each month on the previously scheduled day. - If 7 days or fewer remain until the next scheduled dose, take 1 tablet on the next scheduled day. Thereafter, continue taking 1 tablet each month on the previously scheduled day. - Do not take 2 tablets in the same week. Patients with inadequate dietary intake should supplement with calcium or vitamin D. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment and a creatinine clearance of 30mL/min or higher. Use of this medicine is not recommended for patients with a creatinine clearance below 30mL/min because clinical experience is insufficient. Elderly patients No dose adjustment is necessary.
Efficacy and safety in children 18 years of age or younger have not been studied.
This medication should not be administered to certain patients. For example, patients who are allergic to this medication or its components, patients with untreated hypocalcemia, patients who cannot sit or stand upright for more than 60 minutes, patients with esophageal function issues that hinder proper passage of food, and patients with lactose intolerance or certain genetic problems should not use this. This medication should be used cautiously in patients with significantly impaired kidney function, and expert judgment is needed in such cases. Some patients using this medication may experience side effects such as dyspepsia, nausea, abdominal pain, diarrhea, headache, muscle pain, joint pain, and rash; most side effects are mild or moderate, and discontinuation of treatment has not been necessary. Rarely, symptoms such as esophagitis, esophageal ulcers, dizziness, angioedema, facial swelling, and hives may occur, so any unusual symptoms should be immediately consulted with medical staff. This medication may be associated with serious side effects such as inflammation of the eyes or osteonecrosis of the jaw and surrounding bones, so if there are any unusual symptoms in the eyes or if pain occurs in the jaw area, medical staff should be informed promptly. Before taking this medicine, metabolic abnormalities such as hypocalcemia should be treated, and sufficient calcium and vitamin D intake are necessary. Moreover, patients with esophageal or gastrointestinal issues should exercise caution when taking this medication; if they experience difficulty swallowing, chest pain, or heartburn, they should stop taking it immediately and consult a physician. This medication may hinder absorption if taken with food or medications containing calcium, aluminum, magnesium, or iron, so it is advised to avoid consuming other foods or medications for at least 1 hour after taking it. Pregnant or breastfeeding women are advised not to use this medication, and no special dosage adjustments are necessary for children or the elderly. In case of overdose, gastrointestinal disturbances or hypocalcemia may occur, so do not induce vomiting and ensure that the patient is kept sitting or standing, as dialysis is not effective. Lastly, this medication should be stored out of the reach of children, and any unused medication should be disposed of properly to prevent environmental contamination.
Dyspepsia, nausea, abdominal pain, diarrhea, bloating, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, esophagitis, muscle cramps, musculoskeletal pain, musculoskeletal stiffness, dysphagia, vomiting, esophageal ulcer, stricture, dizziness, low back pain, duodenitis, hypersensitivity reaction, angioedema, facial swelling, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external auditory canal, anaphylaxis, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical femoral neck and intraosseous femoral fractures, atypical fractures of the pelvis, visual disturbances, myasthenia, pruritus
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. Additionally, it is recommended to store the medication at room temperature between 1°C and 30°C. This will help safely maintain the drug's effectiveness.
White to almost white rectangular film-coated tablets
1 tablet / PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowIbandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Gyeongbo Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.